BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 15161435)

  • 1. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
    Budde LS; Hanna NH
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
    Hanauske AR
    Lung Cancer; 2004 Aug; 45 Suppl 1():S121-4. PubMed ID: 15261444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed therapy for malignant pleural mesothelioma.
    Puto K; Garey JS
    Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA drug approval summaries: pemetrexed (Alimta).
    Hazarika M; White RM; Johnson JR; Pazdur R
    Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.
    Manegold C
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):32-6. PubMed ID: 12917819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed-cisplatin combination in mesothelioma.
    Reck M; Gatzemeier U
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):231-7. PubMed ID: 15877521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
    J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pemetrexed].
    Sudoh J; Gemma A
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):1033-8. PubMed ID: 18633241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Update of pemetrexed in thoracic oncology].
    Brechot JM; Morère JF
    Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of a promising new agent--pemetrexed disodium.
    Paz-Ares L; Bezares S; Tabernero JM; Castellanos D; Cortes-Funes H
    Cancer; 2003 Apr; 97(8 Suppl):2056-63. PubMed ID: 12673697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line treatment for malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Gianoncelli L; Lorenzi E; Santoro A
    Cancer Treat Rev; 2010 Feb; 36(1):24-32. PubMed ID: 19879055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of pemetrexed for the treatment of malignant mesothelioma.
    Kindler HL
    Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):49-53. PubMed ID: 15339060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed in malignant pleural mesothelioma.
    Gatzemeier U
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):26-31. PubMed ID: 15655933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer.
    Calvert H
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):2-5. PubMed ID: 12722017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
    Righi L; Papotti MG; Ceppi P; Billè A; Bacillo E; Molinaro L; Ruffini E; Scagliotti GV; Selvaggi G
    J Clin Oncol; 2010 Mar; 28(9):1534-9. PubMed ID: 20177021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nursing considerations for administering pemetrexed (Alimta) in combination with cisplatin for malignant pleural mesothelioma.
    Orbaugh KK
    Clin J Oncol Nurs; 2004 Jun; 8(3):242-7. PubMed ID: 15208818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.